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Sir—We read with interest the article by
Sendi et al. [1] on the safety of intranasal
and injectable influenza vaccines in a
working Swiss population. They report
that, of the 13% of the subjects who
wished to be vaccinated, the nasal route
was the preferred route of administration
for 97%. This is a striking finding, and we
would like to know what information was
provided to the volunteers for them to
make their choices. Indeed, at that time
(winter 2000), to our knowledge, there
were no published safety data with side-
by-side comparisons of the 2 types of vac-
cines; more importantly, there were no data
on immunogenicity (protective antibody
titers) and, therefore, on the efficacy for
humans of the specific intranasal vaccine
used (Nasalflu; Berna Biotech AG). Thus,
we wonder on what grounds the subjects
mentioned “increased efficacy” as a reason
for choosing the nasal spray (23% in table
1 of [1]). Was that information suggested
by the information leaflet?
We made an acceptability assessment
during the winter season of 1999–2000 in
an elderly population attending the Med-
ical Outpatient Clinic, University of Lau-
sanne (Lausanne, Switzerland) as part of
a comparative safety and immunogenicity
trial. Our findings are very different from
those of Sendi et al. [1]. Indeed, only 98
(25%) of 400 elderly persons agreed to be
randomized—in other words, to poten-
tially receive the intranasal vaccine (Na-
salflu; Berna Biotech AG). The main rea-
sons they gave to potentially receive the
mucosal route were “to try” it and because
they “don’t like injections.” The other
75% of persons preferred to receive the
conventional injectable vaccine, with the
main reasons being “one shot and that’s
done,” “I am used to it,” and “I have prob-
lems with my nose.” Because the subjects
were recruited upon usual attendance for
flu vaccination, and because the study pro-
tocol did not include many constraints
(only 1 additional visit and 2 blood draws
were required), it is unlikely that partici-
pation in the trial was the main reason for
the low acceptance of the intranasal vac-
cine. Moreover, during the subsequent
winter season, we let the working personal
of the Medical Outpatient Clinic freely
choose between the intranasal or the in-
tramuscular vaccine. Among those who
accepted vaccination, 19% chose the in-
tranasal route, and 81% chose the intra-
muscular route, which is very far from the
rates of 97% and 3%, respectively, among
the employees of the Canton Basel Stadt
reported by Sendi et al. [1].
The study by Sendi et al. [1] was aimed
primarily at assessing the safety of a new
intranasal vaccine. It definitely contrib-
uted to the identification of an important
severe adverse event (i.e., facial palsy), a
finding that was supported by a later study
[2]. However, the design was not appro-
priate to assess subjects’ preference for one
vaccine or the other, and this may explain
the very different findings between 2
young working communities within the
same country. Thus, we doubt the authors’
conclusions on public preference based on
these data. Such variability calls for well-
designed studies aimed at specifically as-
sessing vaccine route preference among
the public, using standardized informa-
tion based on published peer-reviewed
evidence.
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Reply
Sir—We thank Genton and D’Acremont
[1] for their interest in our article. We
agree with the authors that no data from
a randomized controlled trial comparing
the efficacy of the intranasal versus in-
jectable vaccine are available. However,
immunogenicity and safety data regarding
the virosome-formulated subunit vaccine
containing the heat-labile toxin of Esche-
richia coli were published before winter
2000 [2]. In addition, immunogenicity
and safety data were available from Berna
Biotech AG. It has been argued that the
intranasal vaccine would induce secretory
IgA antibodies (in addition to IgG anti-
bodies) in the nasopharyngeal cavity,
which are able to neutralize influenza vi-
ruses [3]. This may suggest a potentially
higher efficacy [3], although a head-to-
head randomized controlled trial of the
injectable versus intranasal vaccine would
be needed to verify this. In our study, pa-
tients who chose the intranasal vaccine
were less likely to develop influenza-like
